山東新華製藥股份(00719.HK)獲控股股東增持120萬股
格隆匯 6 月 30日丨山東新華製藥股份(00719.HK)發佈公告,2020年6月30日,公司獲維斌有限公司通知,維斌已通過聯交所交易系統競價買入方式增持若干H股股份。維斌為華魯控股集團有限公司的間接全資附屬公司。
2020年6月30日,維斌通過聯交所交易系統以均價約港幣4.18元/股的價格增持公司H股股份共計120萬股,分別佔公司已發行H股股份總數的約0.62%和已發行股份總數的約0.19%,增持總金額約為港幣501.86萬元。
本次增持後,華魯控股(包括透過其附屬公司)合併持有公司股份227,999,060股,約佔公司已發行總股份的36.66%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.